Sensitive and specific high-performance liquid chromatographic assay for 4′-hydroxyflurbiprofen and flurbiprofen in human urine and plasma

被引:36
作者
Hutzler, JM
Frye, RF
Tracy, TS
机构
[1] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA
[2] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA
[3] Univ Pittsburgh, Ctr Clin Pharmacol, Pittsburgh, PA USA
来源
JOURNAL OF CHROMATOGRAPHY B | 2000年 / 749卷 / 01期
关键词
flurbiprofen; 4 '-hydroxyflurbiprofen;
D O I
10.1016/S0378-4347(00)00393-5
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A high-performance liquid chromatographic assay has been developed for the simultaneous quantitation of flurbiprofen and its major metabolite, 4'-hydroxyflurbiprofen, in urine and plasma. No extraction procedure was necessary for analysis of these compounds, which reduced time involved in sample preparation. The analytes were separated on a Brownlee Spheri-5 C-18 column with a mobile phase of acetonitrile-20 mM dibasic potassium phosphate pH 3 buffer (40:60, v/v). Fluorescence detection was utilized with an excitation wavelength of 260 nm and an emission wavelength of 320 nm, providing excellent sensitivity. The limit of quantitation for 4'-hydroxyflurbiprofen and flurbiprofen was 0.25 mug/ml in urine and 0.05 mug/ml and 0.25 mug/ml, respectively, in plasma. All components were eluted within 16 min. Intra-day, inter-day, freeze-thaw, and in process stability were tested for both compounds and the coefficient of variation was less than 14% in all cases. This method provides a sensitive and specific assay for the detection of flurbiprofen and 4'-hydoxyflurbiprofen in urine and plasma and is suitable for use in in vivo studies evaluating the regulation of CYP2C9 activity. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:119 / 125
页数:7
相关论文
共 11 条
[1]  
ASKHOLT J, 1986, ACTA PHARMACOL TOX, V59, P382
[2]  
Frye RF, 2000, CLIN PHARMACOL THER, V67, P109
[3]   STEREOSELECTIVE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF FLURBIPROFEN IN HUMAN PLASMA [J].
GEISSLINGER, G ;
MENZELSOGLOWEK, S ;
SCHUSTER, O ;
BRUNE, K .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 573 (01) :163-167
[4]   Simultaneous analysis of several non-steroidal anti-inflammatory drugs in human urine by high-performance liquid chromatography with normal solid-phase extraction [J].
Hirai, T ;
Matsumoto, S ;
Kishi, I .
JOURNAL OF CHROMATOGRAPHY B, 1997, 692 (02) :375-388
[5]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF THE ENANTIOMERS OF FLURBIPROFEN AND ITS METABOLITES IN PLASMA AND URINE [J].
KNADLER, MP ;
HALL, SD .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 494 :173-182
[6]   IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9 [J].
RETTIE, AE ;
WIENKERS, LC ;
GONZALEZ, FJ ;
TRAGER, WF ;
KORZEKWA, KR .
PHARMACOGENETICS, 1994, 4 (01) :39-42
[7]   DISPOSITION AND METABOLISM OF FLURBIPROFEN IN SEVERAL SPECIES INCLUDING MAN [J].
RISDALL, PC ;
ADAMS, SS ;
CRAMPTON, EL ;
MARCHANT, B .
XENOBIOTICA, 1978, 8 (11) :691-703
[8]   Genetic association between sensitivity to warfarin and expression of CYP2C9*3 [J].
Steward, DJ ;
Haining, RL ;
Henne, KR ;
Davis, G ;
Rushmore, TH ;
Trager, WF ;
Rettie, AE .
PHARMACOGENETICS, 1997, 7 (05) :361-367
[9]   PHARMACOKINETICS OF FLURBIPROFEN IN MAN .1. AREA DOSE RELATIONSHIPS [J].
SZPUNAR, GJ ;
ALBERT, KS ;
BOLE, GG ;
DREYFUS, JN ;
LOCKWOOD, GF ;
WAGNER, JG .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1987, 8 (03) :273-283
[10]   ROLE OF CYTOCHROME-P450 2C9 AND AN ALLELIC VARIANT IN THE 4'-HYDROXYLATION OF (R)-FLURBIPROFEN AND (S)-FLURBIPROFEN [J].
TRACY, TS ;
ROSENBLUTH, BW ;
WRIGHTON, SA ;
GONZALEZ, FJ ;
KORZEKWA, KR .
BIOCHEMICAL PHARMACOLOGY, 1995, 49 (09) :1269-1275